| Objectives:Through to the maternity clinic in our hospital 258 cases of patients with polycystic ovary syndrome during pregnancy were analyzed retrospectively,to compare different treatment before childbirth pregnancy outcome and neonatal outcome in patients with polycystic ovary syndrome,pregnancy treatment in patients with polycystic ovary syndrome and provides the basis for monitoring during pregnancy.Methods:Choose between January 2016 and December 2016 in the first affiliated hospital of kunming medical university maternity clinic always confirmed for 258 cases of pregnant women with polycystic ovary syndrome as the research object,and collected the clinical data were retrospectively analyzed.According to whether pregnancy treatment were divided into treatment group and treatment group:treatment group(143 cases),pregnancy have received oral ethinylestradiol cyproterone piece(Diane 35)at least 3 month treatment,some patients taking low-dose aspirin therapy.In the untreated group(115 cases),no intervention measures were taken before pregnancy.Of two groups of pregnant women with polycystic ovary syndrome during pregnancy complications such as threatened abortion,gestational hypertension,gestational diabetes,cesarean section rate and neonatal outcomes such as preterm birth,such as turning rate of neonatal intensive care unit,and so on and so forth were retrospectively analyzed.Conclusions:1.Comparison of pregnancy patterns between the two groups:134 cases of natural pregnancy(93.7%)and 9 cases of assisted pregnancy(6.3%)in the treatment group.In the untreated group,there were 97 cases of natural pregnancy(84.3%)and 18 cases of assisted pregnancy(15.7%).The natural pregnancy rate of the treatment group was higher than that of the untreated group,and the rate of assisted pregnancy was lower than that of the untreated group.The pregnancy patterns of the two groups were compared,and the results were P<0.05.2.Comparison of delivery methods in the two groups:106 cases(74.1%)of vaginal birth in the treatment group,14 cases of vaginal midwifery(9.8%),and 21 cases(14.7%)of cesarean section.There were 77 cases(67.0%)of eutocia,11 cases(9.6%)of vaginal midwifery and 29 cases(25.2%)of cesarean section.The cesarean section rate of the treatment group was lower than that in the untreated group,and the cesarean section of the two groups was compared with P<0.05.Although the vaginal midwifery rate and eutocia rate were higher in the treatment group than in the untreated group,the vaginal midwifery and eutocia were compared between the two groups,and the results were P>0.05.3.Comparison of pregnancy complications between the two groups:55 cases of threatened abortion(38.5%),42 cases of GDM(29.4%),10 cases of PIH10(7.0%),and 8 cases of pre-eclampsia(5.6%)in the treatment group.In the untreated group,there were 66 cases of threatened abortion(57.4%),48 cases of GDM(41.7%),17 cases of PIH(14.8%)and 15 cases of pre-eclampsia(13.0%).No treatment group threatened abortion,GDM,PIH,preeclampsia is higher than the treatment group,respectively is 0.670 times that of the treatment group(OR 0.670,95%CI 0.517,0.869),0.704 times(OR 0.704,95%CI 0.504,0.982),0.473 times(OR 0.473,95%CI 0.225,0.993)and 0.429(OR 0.429,95%CI 0.188,0.976).The above results were all<0.05 after comparison between the two groups of patients.In the treatment group,30 cases of premature rupture of fetal membranes(21.0%),4 cases of preplacenta(2.8%),25 cases of postpartum hemorrhage(17.5%),1 case of hyperamniotic fluid(0.7%),and 1 case of oligohydramnios(0.7%).In the untreated group,23 cases of premature rupture of membranes(20.0%),2 cases of preplacenta(1.7%),13 cases of postpartum hemorrhage(11.3%),0 cases of hyperamniotic fluid and 3 cases of oligohydramnios(2.6%)occurred.The incidence of premature rupture of membranes,placenta previa,postpartum hemorrhage and excess amniotic fluid in the treatment group was higher than that in the untreated group.The results of comparison between the two groups were P>0.05.Although the incidence of oligohydramnios in the untreated group was higher than that in the treatment group,the above results were P>0.05 after comparison between the two groups.4.Comparison of neonatal conditions:11 cases(7.7%)of neonatal births occurred in the treatment group and NICU23(16.1%).There were 19 cases(16.5%)of neonates in the untreated group,and NICU30(26.1%).Not turn treatment group neonatal premature birth and NICU rate is higher than that of the treatment group,respectively is 0.466 times that of the treatment group(OR 0.466,95%CI 0.231,0.938)and 0.617(OR 0.617,95%CI 0.380,1.001),two groups of patients were compared,the above results are P<0.05).Treatment group of neonatal macrosomia in 3 patients(2.1%),neonatal asphyxia in 3 patients(2.1%),malformation in 2 cases(1.4%),fetal intrauterine death 4 cases(2.8%),neonatal jaundice in 3 patients(2.1%),FGR8 cases(5.6%).Without treatment group of neonatal macrosomia in 3 patients(2.6%),neonatal asphyxia in 2 patients(1.7%),deformity in 1 case(0.9%),fetal intrauterine death in 2 cases(1.7%),neonatal jaundice 8 cases(7.0%),FGR3 cases(2.6%).In the treatment group,the incidence of malformation,FGR and fetal death was higher than that in untreated group,and the two groups were compared,and the results were P>0.05.Although fetal macrosomia,neonatal asphyxia and jaundice in the treatment group were lower than the untreated group,the two groups were compared,and the results were P>0.05.Results:Pregnancy treated in patients with polycystic ovary syndrome and pregnancy compared before treatment of patients with polycystic ovary syndrome,birth weight index is still in the comfort zone,pregnancy complications such as threatened abortion,gestational diabetes,gestational hypertension disease(including hypertension during pregnancy and preeclampsia),lower risk of neonatal adverse outcomes such as preterm birth,to lower the incidence of neonatal intensive care unit.Therefore,for patients with polycystic ovary syndrome,health management should be strengthened,care should be taken before pregnancy,and monitoring should be strengthened during pregnancy to improve maternal and infant outcomes. |
